CVS Health shares powered 7% higher Thursday after the pharmacy and healthcare giant's first-quarter results easily topped ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Earnings came in at $2.25 a share on revenue of $94.6 billion in the quarter, way above analysts' expectations. Continue ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

You can see how EPS has changed over time in the image below ... report on CVS Health's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

You can see how EPS has changed over time in the image below (click on ... This free interactive report on CVS Health's earnings, revenue and cash flow is a great place to start, if you want to ...

Image Source: Zacks Investment Research ... and a below-average P/E despite growth across Optum. CVS Health, a Zacks Rank #3 (Hold) stock, meanwhile, is grappling with challenges like elevated ...